When: $400+ with 50 SMA reclaimed and rising RSI/MACD

Then: Re-enter at current levels or add to position

When: Macro clarity post-FOMC, confirmed momentum signals (MACD histogram contracting, RSI bullish divergence)

Then: Re-enter on demonstrated reversal, not price level alone

REDUCE SLIGHTLY (10-15% trim with ATR-based stops; maintain core conviction)

• AMGN beta of 0.43 is a statistical co-movement measure, not a guarantee of single-session behavior; the 10% drop was macro-driven, not company-specific
• Imdelltra demonstrated statistically significant OS benefit in 563-patient Phase III ES-SCLC; label expansions price in over quarters, not sessions, contradicting 'already in the price' claim
• 115% Imdelltra sales growth is the leading indicator; Phase III data is lagging confirmation of sustainable expansion
• 200 SMA at $355 is an institutional buying zone; April-May 2026 lows of $319 and $333 came on weaker fundamentals than current accelerating revenue and expanding margins
• With 80% probability of Fed hike priced in, the announcement is largely a coin flip; markets price the most likely outcome and react to the surprise component
• Q2 2026 revenue +9.5% YoY, EPS +65% YoY, operating margin 35%, net margin 22.95%, TTM FCF $8.65B, cash grew $8B to $14B in 12 months
• Net debt declined from $48B to $43B; this is a strengthening business experiencing temporary technical/macro air pocket
• The trader's stop at $340 is 9-10% from $375 entry (accepting nearly double the $23 ATR-based risk), anchored to 200 SMA rather than volatility-adjusted position sizing
• Re-entry discipline is notoriously weak; trim-and-re-engage plans typically result in staying underweight through recovery
• Conservative investors should be stewards of capital, not attempt to be heroes on trades; 10-15% trim sized to reduce beta exposure without abandoning a strengthening franchise
• Dividend yield of 2.64% provides income floor during volatility; TTM FCF of $8.65B supports continued shareholder returns
• Re-entry triggers should be based on confirming fundamental momentum through next earnings cycle, not on recapturing 200 SMA

→ vs aggressive: Claims beta of 0.43 is meaningless because AMGN dropped 10% in a session—beta is a statistical measure of co-movement over time, not a guarantee of single-day behavior; this is conflating noise with regime change

→ vs aggressive: Claims the Imdelltra/MariTide catalyst story is 'already in the price'—empirically wrong; label expansions take quarters to price in as commercial uptake materializes, not one session

→ vs aggressive: Treats the 200 SMA as a 'waystation on the way to vacuum'—but $355 is where institutional buyers have stepped in multiple times with weaker fundamentals than present

→ vs aggressive: Uses 'consensus is usually right' on hawkish Fed—that's not how markets work; markets price the most likely outcome and react to the surprise component, not the consensus itself

→ vs neutral: 'Wait and see' approach leaves the firm exposed to either direction without a clear plan; needs explicit re-entry triggers tied to fundamentals, not technical levels

→ vs neutral: The 200 SMA cannot simultaneously be a 'hard floor' at $340 and a 'waystation' at $355—these are contradictory framings that undermine conviction

Trim 15 to 25% of neutral weight to bring the position to about 75 to 85% of benchmark

• Position should be trimmed to 75 to 85% of benchmark (reduce by 15 to 25% of neutral weight)
• Stop should be set at $352 to $355, approximately 2x ATR from entry, right at the 200 SMA confluence
• Re-entry should be gated on post-FOMC macro clarity and confirmed momentum signals (RSI bullish divergence, MACD histogram contraction), not specific price levels
• ATR is $11.48; 2x ATR from $375 entry equals approximately $352
• 200 SMA is at $355, providing a technical floor and volatility-adjusted risk band
• Roughly $9 to $10 per share of downside cushion before next major technical test
• AMGN at $377 has discounted an awful lot of bad news
• Beta of 0.43 and technical breakdown with 6.83 million share distribution day can both be true simultaneously
• Imdelltra Phase III ES-SCLC overall survival data dropped simultaneously with macro selloff; 115% sales growth is a leading indicator not yet fully in consensus estimates
• MACD histogram expansion at negative 9.21 indicates real distribution pattern, not a temporary air pocket
• Stock has broken below 50 SMA, 10 EMA, and lower Bollinger band
• Position should be managed within broader healthcare book managing macro beta rather than as a binary bet

→ vs aggressive: Claims 'consensus is usually right' on hawkish Fed contradict earlier statement that market will 'sell the rumor and buy the fact on dovish surprise' — if consensus is usually right, a dovish surprise wouldn't be a surprise

→ vs aggressive: Beta of 0.43 cannot be invoked as a defensive shield when stock is making a technical breakdown with 6.83 million share distribution day; beta doesn't protect from event-driven gaps

→ vs aggressive: Imdelltra 'already in the price' is weakest link — Phase III data dropped simultaneously with macro selloff; label expansions don't get priced in single sessions, they get priced over quarters

→ vs conservative: 200 SMA 'where institutional buyers step in' is theoretically true but historically untested in this specific spring-to-fall regime transition; moving average is a technical reference point, not a guaranteed fundamental floor

→ vs conservative: 10 to 15% trim is essentially a non-decision that barely reduces exposure while claiming action has been taken; fails to actually mitigate macro risk if technicals are broken and event risk is 5 days away

→ vs conservative: Ignores real technical damage — stock broken below 50 SMA, 10 EMA, lower Bollinger band, with MACD histogram expansion at negative 9.21 is not a 'temporary air pocket,' it's a real distribution pattern

→ vs conservative: $340 stop is too tight; ATR is $11.48, so 2x ATR from $375 equals approximately $352 which sits near the 200 SMA at $355; getting stopped on noise just below where buyers historically appear is poor trade construction

→ vs conservative: Fails to provide any re-entry framework, which is telling; the aggressive's framework of waiting for $400 and 50 SMA recapture is too rigid when macro conditions drive the setup, not price levels